Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2017 Planned number of patients changed from 42 to 50.
- 15 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov